Selected Publications
Janke F*, Stritzke F*, Dvornovich K, Angeles AK, Riediger, AL, Ogrodnik S, Gerhardt S, Regnery S, Schröter P, Bauer L, Weusthoff K, Debus J Görtz M, Sültmann H#, Held T#. Early circulating tumour DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy. Int J Cancer, in press, doi: 10.1002/ijc.3515, 2024.
Angeles AK, Janke F, Daum AK, Reck M, Schneider MA, Thomas N, Christopoulos P, Sültmann H. Integrated circulating tumor DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma. Brit J Cancer 129(1):112-121, 2023.
Daum AK, Schlicker L, Schneider MA, Muley T, Klingmüller U, Schulze A, Christopoulos P, Thomas M, Sültmann H. Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. bioRxiv 2023.08.08.552439; doi: 10.1101/2023.08.08.552439, 2023.
Janke F, Angeles AK, Riediger AL, Bauer S, Reck M, Schneider MA, Muley T, Thomas M, Christopoulos P, Sültmann H. Monitoring progression of ALK-rearranged lung adenocarcinoma using DNA methylation patterns in cell free DNA. Clin. Epigenet 14(1):163, 2022.
Angeles AK*, Christopoulos P*, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, Sültmann H. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precision Oncology, 5(1):100, doi: 10.1038/s41698-021-00239-3, 2021.
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes.
Nature 578(7793), 82-93, 2020.